We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
-5.08%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$4.82B
AUM Growth
-$690M
Cap. Flow
-$124M
Cap. Flow %
-2.58%
Top 10 Hldgs %
17.51%
Holding
1,588
New
254
Increased
693
Reduced
409
Closed
141

Sector Composition

Rank Sector Weight
1 Technology 27.8%
2 Consumer Discretionary 25.32%
3 Communication Services 11.6%
4 Industrials 6.01%
5 Financials 5.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CAH icon
1226
Cardinal Health
CAH
$55.4B
$22K ﹤0.01%
456
+136
+43% +$7.38K
HIPO icon
1227
Hippo Holdings
HIPO
$861M
$22K ﹤0.01%
+193
New +$33.8K
IDYA icon
1228
IDEAYA Biosciences
IDYA
$3.56B
$22K ﹤0.01%
880
+130
+17% +$3.04K
RPTX
1229
DELISTED
Repare Therapeutics
RPTX
$22K ﹤0.01%
850
+10
+1% +$323
SHYG icon
1230
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
$7.6B
$22K ﹤0.01%
+490
New +$22.4K
AMTI
1231
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$22K ﹤0.01%
880
+10
+1% +$317
AMG icon
1232
Affiliated Managers Group
AMG
$9.76B
$21K ﹤0.01%
143
+14
+11% +$2.29K
CMG icon
1233
Chipotle Mexican Grill
CMG
$41.5B
$21K ﹤0.01%
600
KYNB
1234
Kyntra Bio
KYNB
$29.4M
$21K ﹤0.01%
85
+1
+1% +$354
GOSS icon
1235
Gossamer Bio
GOSS
$87M
$21K ﹤0.01%
1,735
+5
+0.3% +$46
ITOS
1236
DELISTED
iTeos Therapeutics
ITOS
$21K ﹤0.01%
805
+5
+0.6% +$131
KROS icon
1237
Keros Therapeutics
KROS
$221M
$21K ﹤0.01%
535
+5
+0.9% +$178
NTRS icon
1238
Northern Trust
NTRS
$33.9B
$21K ﹤0.01%
198
+43
+28% +$4.88K
SNDX icon
1239
Syndax Pharmaceuticals
SNDX
$1.82B
$21K ﹤0.01%
1,115
+15
+1% +$250
STOK icon
1240
Stoke Therapeutics
STOK
$2.11B
$21K ﹤0.01%
840
+5
+0.6% +$139
VNDA icon
1241
Vanda Pharmaceuticals
VNDA
$302M
$21K ﹤0.01%
1,275
+10
+0.8% +$175
VRTX icon
1242
Vertex Pharmaceuticals
VRTX
$126B
$21K ﹤0.01%
120
+30
+33% +$5.86K
AMPH icon
1243
Amphastar Pharmaceuticals
AMPH
$916M
$20K ﹤0.01%
1,100
+15
+1% +$294
ENR icon
1244
Energizer
ENR
$1.55B
$20K ﹤0.01%
524
+52
+11% +$2.09K
INGR icon
1245
Ingredion
INGR
$6.58B
$20K ﹤0.01%
233
+21
+10% +$1.85K
NKTX icon
1246
Nkarta
NKTX
$172M
$20K ﹤0.01%
755
+10
+1% +$317
PPC icon
1247
Pilgrim's Pride
PPC
$6.54B
$20K ﹤0.01%
694
RAPT
1248
DELISTED
RAPT Therapeutics
RAPT
$20K ﹤0.01%
84
+13
+18% +$3.44K
VFC icon
1249
VF Corp
VFC
$5.89B
$20K ﹤0.01%
306
-79
-21% -$6.06K
ARRY icon
1250
Array Technologies
ARRY
$855M
$19K ﹤0.01%
1,030

Similar funds

Penserra Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Penserra Capital Management held 1,588 positions worth $4.82B, down 13% from $5.51B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Penserra Capital Management's Q3 2021 filing shows 254 new, 693 increased, 409 reduced and 141 closed positions. Its largest new stake was DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share: 5,364,893 shares worth $41.8M. The largest sale was Baidu, an estimated $24.6M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • Penserra Capital Management's largest Q3 2021 buy was DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share: 5,364,893 shares worth $41.8M.
  • Penserra Capital Management added most to Analog Devices in Q3 2021, an estimated $22.8M increase.
  • Penserra Capital Management's biggest Q3 2021 reduction was Baidu, cutting an estimated $24.6M.
  • Penserra Capital Management fully exited BlackRock Resources & Commodities Strategy Trust in Q3 2021, selling an estimated $22.3M.
  • Penserra Capital Management's ten largest holdings make up 18% of its $4.82B portfolio in Q3 2021.
  • Penserra Capital Management opened 254 new positions and closed 141 in Q3 2021.
  • Penserra Capital Management's portfolio value fell 13% quarter-over-quarter to $4.82B.

Based on Penserra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.